Convalescent Plasma Therapy – Promising need of the Hour!

-Raddur Samaddar, Team bioXone

While the world is waiting for a COVID-19 vaccine with absolute eagerness, the closest promising immunological treatment that can help stop the rate of the ever-increasing spread of the SARS-CoV-2 virus is the Convalescent Plasma Therapy. This treatment relies upon the transfusion of the anti-viral antibodies from donors to recipients with the help of plasma transfusion. A recent study performed on 103 confirmed COVID-19 Positive Patients comes up with a very innovative Clinical Prediction, between the Donor antibody titer (post 28 days or more of successful cure) and the response of the recipient’s antibodies to the transfusion.

The study was performed on patients with advanced age, fever, absence of myalgia, fatigue, blood type and hospitalization. The multivariate analysis of the clinical and the serological parameters was predicted with the help of Mixed-effects regression models with piecewise linear trends. It was used to characterise the response in 10 recipients with severe COVID-19. A detailed result was obtained after critical analysis.

The Donor antibody titers scaled from 0 to 1:3,892 (anti‐ RBD) and 0 to 1:3,289 (anti‐spike). Higher anti- receptor binding domain and anti-spike titers were associated with increased age, hospitalization for COVID‐19, fever, and absence of myalgia. Critical inferences were also drawn upon the blood type of the recipient. It was seen that AB donors had higher anti‐RBD and anti‐spike than O donors. No toxicity with plasma transfusion was reported, also the titer values increased on the days following the transfusion. The study successfully reported 80% of recipients showed a marked increase in the antibody levels post-transfusion. Clinical Research needs to be conducted further on this domain as this might prevent a thousand infections and curb the spread.

SOURCE:

Madariaga, M.L.L., Guthmiller, J.J., Schrantz, S., Jansen, M.O., Christensen, C., Kumar, M., Prochaska, M., Wool, G., Durkin‐Celauro, A., Oh, W.H., Trockman, L., Vigneswaran, J., Keskey, R., Shaw, D.G., Dugan, H., Zheng, N.‐Y., Cobb, M., Utset, H., Wang, J., Stovicek, O., Bethel, C., Matushek, S., Giurcanu, M., Beavis, K.G., di Sabato, D., Meltzer, D., Ferguson, M.K., Kress, J.P., Shanmugarajah, K., Matthews, J.B., Fung, J.F., Wilson, P.C., Alverdy, J.C. and Donington, J.S. (2020), Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID‐19 convalescent plasma clinical trial. J Intern Med. Accepted Author Manuscript. doi:10.1111/joim.13185

Also read: COVID-19 or flu? Which one to control first?

For more article, visit bioxone.in